2025 annual financial data
Metagenomi Therapeutics 2025 Operating margin
Metagenomi Therapeutics 2025 operating margin with verified reported values.
Direct answer
Operating margin was -380.85%.
Operating income was -96,013,000 USD and net income was -87,868,000 USD.
Operating cash flow was -88,892,000 USD.
Get free Metagenomi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 25,210,000 USD
- Operating income
- -96,013,000 USD
- Net income
- -87,868,000 USD
- Operating cash flow
- -88,892,000 USD